.Attributes Medicine, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA study, after an average follow-up of 11 months, patients along with metastatic gastrointestinal tumors that got biomarker-matched treatments based upon distributing lump DNA profiling showed a better medical perk than those receiving unmatched therapy.